Edition:
United States

Delcath Systems Inc (DCTH.OQ)

DCTH.OQ on NASDAQ Stock Exchange Capital Market

0.09USD
30 Mar 2017
Change (% chg)

$-0.00 (-1.16%)
Prev Close
$0.09
Open
$0.09
Day's High
$0.09
Day's Low
$0.08
Volume
480,030
Avg. Vol
1,001,887
52-wk High
$6.72
52-wk Low
$0.08

Latest Key Developments (Source: Significant Developments)

Delcath announces 2016 financial results
Wednesday, 29 Mar 2017 08:00am EDT 

Delcath Systems Inc : Delcath announces 2016 financial results . Q4 revenue $700,000 .Believes it has sufficient capital and access to committed capital to fund its operating activities through q1 of 2018.  Full Article

Delcath systems's independent registered public accounting firm issued report
Wednesday, 29 Mar 2017 06:27am EDT 

Delcath Systems Inc : Delcath Systems - Co's independent registered public accounting firm issued report on March 28 regarding audit of co's financial statements as of Dec 31, 2016 . Delcath Systems - March 28 report included explanatory paragraph describing existence of conditions raising doubt about co continuing as going concern .Delcath Systems - "We do not expect to generate significant revenue for the foreseeable future".  Full Article

Delcath Systems enters agreement with holders of more than 55 pct of aggregate principal amount of senior secured convertible notes Due Dec 29, 2017
Thursday, 23 Feb 2017 08:35am EST 

Delcath Systems Inc : Delcath Systems - co, holders of more than 55 pct of aggregate principal amount of senior secured convertible notes due Dec 29, 2017 entered agreement .Delcath Systems - agreement to temporarily reduce conversion price for conversions at option of holders of notes to $0.14/share from Feb 23 to March 2.  Full Article

Barbra C. Keck became CFO of Delcath Systems effective Feb. 21- SEC filing
Wednesday, 22 Feb 2017 04:28pm EST 

Delcath Systems Inc :Effective February 21, 2017, Barbra C. Keck became chief financial officer of company - SEC filing.  Full Article

Empery Asset Management LP dissolves passive stake in Delcath Systems
Tuesday, 31 Jan 2017 02:05pm EST 

: Empery Asset Management LP dissolves passive stake in Delcath Systems Inc as of Dec 30, 2016 - SEC filing .Empery Asset Management LP previously reported a passive stake of 5.14% in Delcath Systems Inc as of Sept 30, 2016.  Full Article

Delcath announces patient treatment in intrahepatic Cholangiocarcinoma study
Thursday, 12 Jan 2017 08:30am EST 

Delcath Systems Inc : Delcath Systems Inc - patient treatment, data collection for intrahepatic cholangiocarcinoma (ICC) cohort of European Phase 2 HCC/ICC study is ongoing . Delcath Systems Inc - will announce interim results for cohort once data are fully mature . Delcath Systems Inc - "original goal to obtain an efficacy signal for Phase 2 ICC cohort has been satisfied" .Delcath Systems Inc - "PHP(®) therapy does, indeed, "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation.".  Full Article

Delcath announces proposed public offering of common stock and warrants
Thursday, 29 Sep 2016 05:40pm EDT 

Delcath Systems Inc : Delcath announces proposed public offering of common stock and warrants .Intends to use net proceeds for funding of clinical trials, commercialization of its products, obtaining regulatory approvals etc.  Full Article

Delcath posts Q2 loss of $4.41/share
Tuesday, 16 Aug 2016 08:00am EDT 

Delcath Systems Inc: Delcath announces second quarter financial results . Qtrly loss per share $4.41 . Q2 revenue $500,000 .Delcath believes it has sufficient capital to fund its operating activities through end of 2017.  Full Article

Delcath Systems Inc announces initiation of Phase 3 trial of Melphalan/HDS System
Wednesday, 20 Jan 2016 08:00am EST 

Delcath Systems Inc:Announces the initiation of a Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with hepatic dominant ocular melanoma (OM).Says moffitt cancer center begins patient enrollment in focus trial; study results to support u.s. new drug application.  Full Article

Delcath Systems Inc receives orphan drug designation from FDA for melphalan to treat cholangiocarcinoma
Monday, 20 Jul 2015 08:00am EDT 

Delcath Systems Inc:Says that U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for melphalan for treatment of cholangiocarcinoma.  Full Article

More From Around the Web

BRIEF-Delcath announces 2016 financial results

* Believes it has sufficient capital and access to committed capital to fund its operating activities through q1 of 2018 Source text for Eikon: Further company coverage: